US 12,422,442 B2
Markers and their use in brain injury
Jean-Charles Sanchez, Geneva (CH); and Joan Montaner, Barcelona (ES)
Assigned to UNIVERSITE DE GENEVE, Geneva (CH); and FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON—INSTITUT DE RECERCA, Barcelona (ES)
Filed by UNIVERSITE DE GENEVE, Geneva (CH); and FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON—INSTITUT DE RECERA, Barcelona (ES)
Filed on Dec. 23, 2021, as Appl. No. 17/560,297.
Application 16/698,363 is a division of application No. 15/516,543, abandoned, previously published as PCT/EP2015/001946, filed on Oct. 5, 2015.
Application 17/560,297 is a continuation in part of application No. 16/698,363, filed on Nov. 27, 2019, abandoned.
Claims priority of application No. 14003422 (EP), filed on Oct. 6, 2014; and application No. 15002459 (EP), filed on Aug. 19, 2015.
Prior Publication US 2022/0137072 A1, May 5, 2022
Int. Cl. G01N 33/68 (2006.01)
CPC G01N 33/6896 (2013.01) [G01N 2333/47 (2013.01); G01N 2333/4727 (2013.01); G01N 2333/521 (2013.01); G01N 2333/70503 (2013.01); G01N 2333/775 (2013.01); G01N 2333/902 (2013.01); G01N 2333/91091 (2013.01); G01N 2333/91177 (2013.01); G01N 2800/28 (2013.01); G01N 2800/60 (2013.01)] 8 Claims
 
1. A method of treatment of a disease or disorder, wherein the disease or disorder is a traumatic brain injury (TBI), the method comprising:
a. obtaining a sample from the human patient;
b. measuring a level of heart fatty-acid-binding protein (H-FABP) and a level of glial fibrillary acidic protein (GFAP) in the sample, and comparing the level of H-FABP and the level of GFAP to reference levels of H-FABP and GFAP to identify the patient as having the traumatic brain injury when the measured levels are higher than the reference levels; and
c. administering a treatment to the patient;
wherein the treatment comprises one or more pain reliving agents, one or more anti-seizure agents, one or more coma-inducing agents, one or more diuretic agents, one or more anti-anxiety agents, one or more anti-depressive agents, one or more hyperosmolar therapies, one or more cognitive therapies, one or more rehabilitation therapies including physical, occupational, and speech therapies, one or more therapeutic hypothermia therapies, one or more stem cell therapies, one or more surgical therapies, rest, head elevation, hyperventilation, or combinations thereof.